This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

The UK's benchmark FTSE 100 index fell on Wednesday, dragged by healthcare shares after GSK warned of lower annual vaccine ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...

For anyone who wants to understand GSK's profit beyond the statutory numbers, it's important to note that during the last ...

UK pharma major GSK looked set to close Wednesday’s trading around 3% lower. The London-based drugmaker earlier presented its ...

GSK shares (UK:GSK) (GSK) slumped 3% in London trade and are now down 3% on the year. Sean Conroy, an analyst at U.K. broker Shore Capital, said vaccines concerns had been holding back the company ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

The University of Cambridge and GSK (GlaxoSmithKline) have started a new five-year collaboration aiming to improve outcomes ...

The collaboration agreement was signed by Dr. Ramadan Al Blooshi, Advisor to the Director General and Acting Director of the ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...